How to Transfer In-Process R&D to a Finite-Lived Intangible and Begin Amortization Upon Reaching Technological Feasibility
Reclassifying IPR&D from an indefinite-lived intangible to a finite-lived amortizable intangible when a development project reaches technological feasibility and commercial viability post-acquisition.
| Account Name | Type | Debit ($) | Credit ($) |
|---|---|---|---|
| Intangible Asset — Developed Technology (Finite-Lived, from IPR&D) | Asset (+) | 22,000,000.00 | - |
| In-Process R&D (Indefinite-Lived — Reclassified) | Asset (-) | - | 22,000,000.00 |
| Amortization Expense — Developed Technology (Post-Feasibility) | Expense (+) | 2,200,000.00 | - |
| Accumulated Amortization — Developed Technology | Asset (-) | - | 2,200,000.00 |
💡 Accountant's Note
IPR&D recognized in a business combination is an indefinite-lived intangible — not amortized, subject to annual impairment testing. When the underlying R&D project reaches technological feasibility: (1) Reclassify from IPR&D (indefinite) to developed technology (finite-lived), (2) Begin amortizing over the expected useful life, (3) No catch-up amortization for the period the asset was IPR&D (amortization prospective from feasibility date). If the project is abandoned: write off the entire IPR&D balance to expense immediately. The useful life for the now-developed technology reflects the expected period of economic benefit (product lifecycle, competitive dynamics, patent expiration).
Practitioner & Systems Framework
💻 ERP Architecture
Maintain an IPR&D project register tracking: (1) original FV at acquisition, (2) subsequent costs to complete (expensed as incurred per ASC 730 — post-acquisition R&D is expensed), (3) stage of development (% completion), (4) technological feasibility milestones, (5) commercial release date. The useful life assigned upon reclassification must be supported by product lifecycle analysis. An IPR&D project that takes longer than expected to reach feasibility may be impaired — perform the indefinite-lived impairment test annually or when impairment indicators appear.
⚠️ Audit Flags
Auditors track IPR&D projects individually — each project must be assessed for impairment annually and for feasibility achievement each reporting period. Common errors: (1) failing to perform the annual impairment test on IPR&D balances (treating them as if they don't require testing), (2) beginning amortization before the feasibility determination is documented, (3) not writing off abandoned projects promptly. For pharmaceutical acquisitions with multiple compounds in IPR&D, each compound is tested separately.
📄 Required Documentation
IPR&D project register (project name, acquisition-date FV, stage at acquisition, subsequent milestones), technological feasibility determination memo (what criteria are met, evidence of feasibility), reclassification entry documentation, useful life assessment (post-feasibility product lifecycle analysis), annual IPR&D impairment test documentation, project abandonment documentation (if applicable).
Automate this entry with the JEH Accounting Suite
Stop doing manual entry. Our VBA-powered ERP automatically generates your ledgers, Trial Balance, and Financial Statements.
No Subscriptions. Own your data.
Expert Analysis by Qusai Ahmad
General Accountant Supervisor & IFRS Specialist
Specialized in SAP GUI automation and Middle Eastern tax compliance. Building digital tools for the next generation of finance leaders.
Related Journal Entries
Mergers & Acquisitions
How to Record the Initial Recognition of a Business Combination Using the Acquisition Method Under ASC 805
Mergers & Acquisitions
How to Expense M&A Transaction Costs in the Period Incurred Rather Than Capitalizing Them Into Goodwill
Mergers & Acquisitions